ZIOP-PGEN Fundamental & Technical Discussion Board - CAR T Cells: Off the Shelf and On the Mark - ZIOP-PGEN Fundamental & Technical Discussion Board - InvestorVillage


ZIOP-PGEN Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: ZIOP-PGEN Fundamental & Technical Discussion Board   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  24986 of 25208  at  9/26/2021 2:15:13 PM  by

clsm

The following message was updated on 9/26/2021 6:18:39 PM.

 In response to msg 24982 by  dachmeister4u
view thread

Re: CAR T Cells: Off the Shelf and On the Mark

The biology of NK cells is different to T-cells. The former have rapid and potent cytotoxic, however, they do not typically expand upon encounter with antigen and lack long-term persistence.

FATE's FT516 (an iPSC-derived NK cell) has a high-affinity, non-cleavable CD16 Fc receptor to augment ADCC. FT596 (another iPSC-derived NK cell) has that, a CD19 CAR (optimised for NKs) and an IL-15RF.

With FT516, patients got three doses (either 30M, 90M or 300M per dose, on days 1/8/15), three doses of IL-2 with each infusion, and were given two cycles along with a single dose of ritiuximab (an anti-CD20 mAb). The ORR for the 90M dose was 75% and three-month CR rate was 50%. For the 300M dose, it was 71% and 57%, respectively. Five of 11 have ongoing responses at 4.6-9.5+ months.

With FT596, patients got a single dose (+/- ritiuximab), no IL-2 (due to it having cell-intrinsic cytokine support) and single cycle. The ORR for the 30M (both single and combo) dose was 17%, for the 90M dose it was 63%, and for the 300M it was 83%.

Those enrolled all had R/R B-cell lymphomas, and a number had been treated with either anti-CD19 bispecific antibodies or CAR-T. One even failed both anti-CD19 and anti-CD20 CAR-T's. The next data update will be at ASH.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...